What drove the step-up in profitability this quarter?

Revenue grew 35% while product gross margin expanded 4 points to 89%, and SG&A as a share of product sales fell from 41% to 37%. R&D and SG&A dollars both rose, but more slowly than revenue, producing GAAP operating income of $250 million versus $11 million a year earlier.

Did management change its full-year outlook?

Yes, modestly higher. Total revenue guidance moved up $100 million at both ends to $6.3–$6.5 billion, and GAAP operating income guidance rose $50 million to $750–$850 million. GAAP operating expense guidance was unchanged at $4.7–$4.9 billion, and non-GAAP operating income guidance rose to $1.45–$1.55 billion.

Could the company record a large tax benefit, and how would it affect reported earnings?

Management said current earnings may provide enough positive evidence to reverse some valuation allowances in 2026, which would produce a material one-time tax benefit and boost GAAP net income. The timing and amount are uncertain, and until a reversal, income tax expense should track earnings under the historical relationship. Q1 income tax expense was $32 million.

What are the key regulatory and clinical catalysts to watch?

In 1H 2026: an FDA action on sonrotoclax for R/R mantle cell lymphoma, a Phase 3 MANGROVE interim analysis of BRUKINSA in first-line MCL, and a Japan regulatory action on TEVIMBRA in first-line gastric cancer. In 2H 2026: an FDA action on TEVIMBRA plus ZIIHERA in first-line HER2-positive GEA (Priority Review), and a potential accelerated approval submission for BGB-16673 in R/R CLL.

What should investors be cautious about?

Non-GAAP metrics exclude share-based compensation ($123 million in Q1), so GAAP results are the more conservative view. Operating expenses rose 16% on a GAAP basis, the company has $1.08 billion of debt and a $904 million sale-of-future-royalty liability, and accounts receivable and inventories both grew faster than the prior year. Results also depend on continued BRUKINSA growth and on pipeline readouts and regulatory decisions that are not guaranteed.

ONC/BEIGF 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed May 6, 2026. Cited figures are marked; the original filing is the authoritative source.

BeOne Medicines (NASDAQ: ONC) reported first-quarter 2026 results that showed strong top-line momentum and a sharp improvement in profitability.

Total revenue rose 35% year over year to $1.51 billion^a, led by foundational BRUKINSA (zanubrutinib), with global BRUKINSA sales of $1.1 billion (up 38%) and U.S. BRUKINSA sales of $761 million (up 35%). GAAP income from operations swung to $250 million from $11 million a year earlier, GAAP net income reached $227 million versus $1 million, and free cash flow was $161 million versus a $12 million outflow. Gross margin on product sales expanded to 89% from 85%, and SG&A fell to 37% of product sales from 41%, pointing to meaningful operating leverage.

The company raised its full-year 2026 guidance for total revenue to $6.3^b–$6.5 billion (from $6.2–$6.4 billion) and for GAAP operating income to $750–$850 million (from $700–$800 million). Non-GAAP operating income guidance was raised to $1.45–$1.55 billion. Management also flagged a possible material income tax benefit later in 2026 if valuation allowances on deferred tax assets are reversed, though the timing and size are uncertain.

Investors should note that operating expenses are growing faster than revenue in percentage terms, that the company carries $1.08 billion^c of debt and a $904 million sale-of-future-royalty liability, and that the press release's non-GAAP metrics exclude share-based compensation of $123 million in the quarter. On the pipeline side, management highlighted the fixed-duration sonrotoclax plus BRUKINSA combination as a potential first-line CLL standard of care, and BGB-16673 (BTK CDAC) as a potential first-in-class option in relapsed or refractory disease. Near-term catalysts include an FDA decision on sonrotoclax in R/R MCL in 1H 2026, a Phase 3 MANGROVE interim analysis in first-line MCL in 1H 2026, and an FDA decision on TEVIMBRA plus ZIIHERA in first-line HER2-positive gastroesophageal adenocarcinoma in 2H 2026, following Priority Review acceptance.

02—Key points

Key Highlights

Total revenue of $1.51 billion, up 35% year over year; net product revenue of $1.49 billion, up 34%.
BRUKINSA global sales of $1.1 billion (up 38%), with U.S. sales of $761 million (up 35%), reinforcing its role as the core revenue driver.
GAAP operating income of $250 million versus $11 million a year earlier; GAAP net income of $227 million versus $1 million; GAAP diluted EPS per ADS of $1.96.
Product gross margin rose to 89% from 85%, aided by higher BRUKINSA mix and lower production costs; SG&A fell to 37% of product sales from 41%.
Free cash flow of $161 million, versus a $12 million outflow in Q1 2025; cash, equivalents and restricted cash rose to $4.85 billion.
Raised FY2026 guidance: total revenue to $6.3–$6.5 billion and GAAP operating income to $750–$850 million, while GAAP operating expense guidance held at $4.7–$4.9 billion.
Possible material income tax benefit in 2026 if valuation allowances are reversed; timing and magnitude remain uncertain.

03—Questions

Frequently Asked Questions

What drove the step-up in profitability this quarter?
Revenue grew 35% while product gross margin expanded 4 points to 89%, and SG&A as a share of product sales fell from 41% to 37%. R&D and SG&A dollars both rose, but more slowly than revenue, producing GAAP operating income of $250 million versus $11 million a year earlier.
Did management change its full-year outlook?
Yes, modestly higher. Total revenue guidance moved up $100 million at both ends to $6.3–$6.5 billion, and GAAP operating income guidance rose $50 million to $750–$850 million. GAAP operating expense guidance was unchanged at $4.7–$4.9 billion, and non-GAAP operating income guidance rose to $1.45–$1.55 billion.
Could the company record a large tax benefit, and how would it affect reported earnings?
Management said current earnings may provide enough positive evidence to reverse some valuation allowances in 2026, which would produce a material one-time tax benefit and boost GAAP net income. The timing and amount are uncertain, and until a reversal, income tax expense should track earnings under the historical relationship. Q1 income tax expense was $32 million.
What are the key regulatory and clinical catalysts to watch?
In 1H 2026: an FDA action on sonrotoclax for R/R mantle cell lymphoma, a Phase 3 MANGROVE interim analysis of BRUKINSA in first-line MCL, and a Japan regulatory action on TEVIMBRA in first-line gastric cancer. In 2H 2026: an FDA action on TEVIMBRA plus ZIIHERA in first-line HER2-positive GEA (Priority Review), and a potential accelerated approval submission for BGB-16673 in R/R CLL.
What should investors be cautious about?
Non-GAAP metrics exclude share-based compensation ($123 million in Q1), so GAAP results are the more conservative view. Operating expenses rose 16% on a GAAP basis, the company has $1.08 billion of debt and a $904 million sale-of-future-royalty liability, and accounts receivable and inventories both grew faster than the prior year. Results also depend on continued BRUKINSA growth and on pipeline readouts and regulatory decisions that are not guaranteed.

04—Continue

← View all 8-K filings